Palanisamy Amudha, Reeves-Daniel Amber M, Freedman Barry I
Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1053, USA.
Pediatr Nephrol. 2014 Sep;29(9):1485-92. doi: 10.1007/s00467-013-2531-7. Epub 2013 Jun 9.
Dramatic improvements have been seen in short-term kidney allograft survival over recent decades with introduction of more potent immunosuppressant medications and regimens. Unfortunately, improvements in long-term graft survival have lagged behind. The genomics revolution is providing new insights regarding the potential impact of kidney donor genotypes on long-term graft survival. Variation in the donor apolipoprotein L1 (APOL1), caveolin 1 (CAV1), and multi-drug resistance 1 encoding P-glycoprotein genes (ABCB1) are all associated with graft survival after kidney transplantation. Although the precise mechanisms whereby these donor gene variants confer risk for graft loss have yet to be determined, these findings provide novel opportunities for modifying interactive environmental factors and optimizing kidney allocation with the ultimate goal of improving long-term graft survival rates.
近几十年来,随着更有效的免疫抑制药物和方案的引入,肾移植短期存活率有了显著提高。不幸的是,长期移植存活率的提高却滞后了。基因组学革命为肾供体基因型对长期移植存活率的潜在影响提供了新的见解。供体载脂蛋白L1(APOL1)、小窝蛋白1(CAV1)以及编码P-糖蛋白的多药耐药1基因(ABCB1)的变异均与肾移植后的移植物存活相关。尽管这些供体基因变异导致移植物丢失风险的确切机制尚未确定,但这些发现为改变相互作用的环境因素和优化肾脏分配提供了新的机会,最终目标是提高长期移植存活率。